Eden Research plc Total Assets
Eden Research plc total assets. Based on the latest financial reports, Eden Research plc (EDEN) holds total assets worth GBX13.46 Million GBX (≈ $1.64K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see EDEN stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Eden Research plc (2004–2026)
Total assets of Eden Research plc from 2004 to 2026. This chart illustrates how Eden Research plc's total assets have evolved over time, based on quarterly financial data. See EDEN share price today for real-time trading data and today's change.
Eden Research plc - Asset Composition Analysis
Eden Research plc Total Assets Breakdown (March 2026)
Eden Research plc total assets breakdown as of March 2026. Eden Research plc's total assets of GBX13.46 Million consist of 40.8% current assets and 59.2% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 9.3% |
| Accounts Receivable | GBX4.13 Million | 25.3% |
| Inventory | GBX581.86K | 3.6% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX8.69 Million | 53.2% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2004–2026)
This chart illustrates how Eden Research plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore EDEN net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eden Research plc's current assets represent 40.8% of total assets in 2026, an increase from 1.6% in 2004.
- Cash Position: Cash and equivalents constituted 9.3% of total assets in 2026, up from 0.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, a decrease from 98.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 53.2% of total assets.
Eden Research plc Competitors by Total Assets
Key competitors of Eden Research plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Huapont Life Sciences Co Ltd
SHE:002004
|
China | CN¥29.25 Billion |
|
Cangzhou Dahua Co Ltd
SHG:600230
|
China | CN¥6.04 Billion |
|
Bharat Rasayan Limited
NSE:BHARATRAS
|
India | Rs14.33 Billion |
|
Kyung Nong Corporation
KO:002100
|
Korea | ₩551.19 Billion |
|
Khaitan Chemicals & Fertilizers Limited
NSE:KHAICHEM
|
India | Rs6.82 Billion |
|
Insumos Agroquimicos SA
BA:INAG
|
Argentina | AR$45.35 Billion |
|
Nufarm Ltd
AU:NUF
|
Australia | AU$4.80 Billion |
|
Rama Phosphates Limited
NSE:RAMAPHO
|
India | Rs7.19 Billion |
Eden Research plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.17 | 3.80 | 9.51 |
| Quick Ratio | 1.90 | 3.53 | 9.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX2.82 Million | GBX6.44 Million | GBX9.81 Million |
Eden Research plc - Advanced Valuation Insights
This section examines the relationship between Eden Research plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.42 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 6.1% |
| Total Assets | GBX16.34 Million |
| Market Capitalization | $332.34K USD |
Valuation Analysis
Below Book Valuation: The market values Eden Research plc's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Eden Research plc's assets grew by 6.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Eden Research plc (2004–2026)
The table below shows the annual total assets of Eden Research plc from 2004 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | GBX16.34 Million ≈ $1.99K |
+6.08% |
| 2024-12-31 | GBX15.41 Million ≈ $1.87K |
-7.16% |
| 2023-12-31 | GBX16.59 Million ≈ $2.02K |
+28.53% |
| 2022-12-31 | GBX12.91 Million ≈ $1.57K |
-14.08% |
| 2021-12-31 | GBX15.03 Million ≈ $1.83K |
-11.21% |
| 2020-12-31 | GBX16.92 Million ≈ $2.06K |
+90.92% |
| 2019-12-31 | GBX8.86 Million ≈ $1.08K |
-3.85% |
| 2018-12-31 | GBX9.22 Million ≈ $1.12K |
-12.90% |
| 2017-12-31 | GBX10.59 Million ≈ $1.29K |
+35.79% |
| 2016-12-31 | GBX7.80 Million ≈ $948.54 |
+16.71% |
| 2015-12-31 | GBX6.68 Million ≈ $812.70 |
+4.35% |
| 2014-12-31 | GBX6.40 Million ≈ $778.85 |
-2.03% |
| 2013-12-31 | GBX6.53 Million ≈ $794.96 |
-14.06% |
| 2012-12-31 | GBX7.60 Million ≈ $925.02 |
-8.34% |
| 2011-12-31 | GBX8.29 Million ≈ $1.01K |
+0.18% |
| 2010-12-31 | GBX8.28 Million ≈ $1.01K |
-6.72% |
| 2009-12-31 | GBX8.88 Million ≈ $1.08K |
+3.64% |
| 2008-12-31 | GBX8.56 Million ≈ $1.04K |
-4.02% |
| 2007-12-31 | GBX8.92 Million ≈ $1.09K |
+17.63% |
| 2006-12-31 | GBX7.59 Million ≈ $922.90 |
-11.87% |
| 2005-12-31 | GBX8.61 Million ≈ $1.05K |
-14.77% |
| 2004-12-31 | GBX10.10 Million ≈ $1.23K |
-- |
About Eden Research plc
Eden Research plc, together with its subsidiaries, biopesticides and plastic-free encapsulation technology for use in the global crop protection, animal health, and consumer products industries in Europe and the United Kingdom. The company offers foliar disease and insect control, open field and greenhouses, soil pests, post-harvest shelf-life extension, and seed treatments under the Mevalone and… Read more